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Cancer-testis antigen 7 (CT7, or melanoma-associated
antigen (MAGE)-C1) is the most frequently and consistently
expressed MAGE antigen in multiple myeloma (MM). CT7 is
an independent negative prognostic factor for MM, exhibits
a tissue-restricted expression pattern, and is highly
expressed during all stages of disease. Consequently, CT7 is
regarded as a potential target for immunotherapeutic strat-
egies in MM.
We sought to characterize CT7 protein expression in
the bone marrow (BM) of MM patients (pts) following allo-
geneic T cell-depleted (TCD)-HSCT, and to examine the
signiﬁcance of CT7-speciﬁc cellular and humoral immune
responses in these pts. We further aimed to determine CT7-
derived immunogenic epitopes and their associated allelic
restrictions.
Expression of CT7 in neoplastic CD138+ plasma cells was
evaluated by immunohistochemistry double staining in BM
biopsies from15 pts. CT7 expressionwas present in 13/15 pts.
Longitudinal analyses conducted in 10 of these pts showed
that low levels of CT7 protein were associated with better
outcomes. Conversely, the presence of CT7 protein in a high
percentage of myeloma cells was associated with a poorer
prognosis.
The nonamer FLAMLKNTV was predicted to have the
highest binding indices for HLA-A*0201 by reverse immu-
nology. Indeed, we conﬁrmed epitope-speciﬁc reactivity by
measuring intracellular IFN-g production to this peptide in
PBMC and BMMC from HLA-A*0201-expressing pts. The
tetramer HLA-A*0201-CT7-1087-1095 was generated to permit
longitudinal monitoring of CT7-speciﬁc T cell frequencies.
CT7-speciﬁc T cell frequencies were quantiﬁed by
tetramer staining in PBMC from 4 HLA-A*0201+ MM pts. Two
pts who developed marked tetramer+ T cell responses (up to
17.7 CD8+T cells/mL PB) entered CR. In contrast, 2 pts who
failed to develop prominent tetramer+ T cell responses
exhibited progressive disease. Phenotypic analyses revealed
the predominant presence of central memory CT7-speciﬁc T
cells in the BM,while effector memory cells dominated in the
PB. These initial clinical results suggest a potential relation-
ship between CT7-speciﬁc T cell frequencies and disease
course.
Humoral responses to a panel of tumor antigens,
including CT7, were examined longitudinally in 10 pts.
Analyses of CT7-speciﬁc antibody titers in one pt revealed
a response to a single CT7-derived peptide (CT71029-1048).
This response developed at a later time point than T cell
responses occurring in the same pt.
Finally, we report CT7-speciﬁc cytotoxic activity against
the CT7-expressing HLA-A*0201+ MM cell line U266 by T
cells expanded from a donor-reconstituted HLA-A*0201+MM
pt. Together, these results provide evidence of CT7-speciﬁc T
and B-cell responses that are able to target MM cells in
treatment responsive patients. Adoptive immunotherapeuticapproaches targeting CT7 may therefore prove useful in pts
with MM post allogeneic TCD-HSCT.86
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Background: Transformation of follicular lymphoma (FL) to
diffuse large B cell lymphoma (DLBCL) occurs in 30% of cases
at 10 years. Historically, survival with chemotherapy is poor.
Limited data are available on the role of autologous or allo-
geneic hematopoietic cell transplantation (autoHCT or
alloHCT) for DLBCL transformed from FL.
Methods: Descriptive analysis of 155 patients (age>18 years)
from 89 centers with transformation of FL to DLBCL reported
to the CIBMTR who had autoHCTor alloHCT from 1990-2009.
Pathology reports were reviewed in all cases to conﬁrm
transformation of FL to DLBCL. This is the largest epidemio-
logic series analyzing outcomes of HCT in transformed
DLBCL.
Results: Patients were classiﬁed into 3 groups consisting of
autoHCT (N¼108), alloHCT (N¼33), alloHCT (N¼14) after
prior autoHCT (performed for FL) with median ages of 56, 49,
51 years (yr) who received median of 3, 4, 5 lines of
chemotherapy prior to HCT, respectively. AutoHCT, alloHCT,
and alloHCTwith prior autoHCTgroups had 5 yr relapse rates
54% (95% conﬁdence intervals [CI] 45-64%), 33% (95% CI 17-
50%), 38% (95% CI 15-65%); 1 yr treatment related mortality
8% (95% CI 3-14%), 41% (95% CI 25-58%), 62% (95% CI 35-85%);
5 yr progression free survival (PFS) 36% (95% CI 27-46%), 18%
(95% CI 6-35%), 0%; 5 yr overall survival (OS) 50% (95% CI 40-
60%), 22% (95% CI 8-41%), 7% (95% CI 0-26%) respectively. The
size of the cohort did not allow multivariate analysis.
Univariate survival analysis of associations between risk
factors and post autoHCT and alloHCT outcomes showed age,
Karnofsky performance status, rituxan use, extranodal
disease and disease status at HCT (complete remission versus
primary induction failure) were not signiﬁcant factors. Use of
HLA identical sibling vs unrelated donors, ATG/campath vs
none, did not impact PFS/ OS after alloHCT. Chemotherapy vs
total body irradiation-based conditioning for autoHCT had
improved 3 yr PFS (46% [95% CI 35-57%] vs 24% [95% CI 9-
43%]; P ¼ .04); but 3 yr OS was not signiﬁcantly different.
Transformation >1 yr vs <1yr from diagnosis (dx) yielded
improvement in 1 yr PFS for the autoHCT (61% [95% CI 51-
71%] vs 29% [95% CI 11-53%]; P ¼ .01) and alloHCT groups
(44% [95% CI 24-64%] vs 11% [95% CI 0-38%]; P ¼ .03).
Transformation > 1 yr vs <1 yr from dx also had better 2 yr
OS in the alloHCT group (43% [95% CI 24-64%] vs 11% [95% CI
0-38%]; P ¼ .03). Time from dx to transformation was not
associated with OS after autoHCT. The Kaplan Meier graph
for PFS/ OS showed a plateau after 40 months only for
autoHCT group.
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provide durable PFS and OS in this high risk cohort. Trans-
formation to DLBCL > 1 year after dx of FL is associated with
improved 1 yr PFS in both autoHCT and alloHCT groups, and
superior 2 yr OS in the alloHCT group compared to those
cases with transformation< 1year from dx of FL. Patients
with primary induction failure also beneﬁt from consolida-
tion with HCT.PEDIATRIC DISORDERS ORAL87
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Treosulfan has several characteristics that make it
appealing for use in conditioning, including bypass of
hepatic enzyme activation, a highly predictable pharma-
cokinetic proﬁle, and sufﬁcient immunosuppressive
activity to allow for engraftment of donor cells across
histocompatibility barriers. Here we report the preliminary
results of a phase II multi-center clinical trial for 25
patients with non-malignant diseases [primary immune
deﬁciency diseases (PIDD, n¼12), hemophagocytic lym-
phohistiocytosis (HLH; n¼5), inherited bone marrow
failure syndromes (n¼4), and other non-malignant
diseases (n¼4)] who received allogeneic hematopoietic cell
transplantation (HCT) from October 2009 to July 2012.
Patients were given HLA-matched related (n¼2) or unre-
lated (n¼23) marrow (n¼23) or G-CSF mobilized periph-
eral blood stem cell (n¼2) grafts following conditioning
with treosulfan (total dose: 42 grams/m2), ﬂudarabine
(total dose: 150 mg/m2), +/- thymoglobulin (rabbit ATG,
n¼16; total dose: 6 mg/kg). All patients received tacroli-
mus and methotrexate for GVHD prevention. Median age
at HCT was 8.3 (range, 0.4-30.5) years. Three patients had
received a previous allogeneic HCT. Median time to
neutrophil engraftment was 22 days. Of the 25 evaluable
patients, all had full (>95%; n¼19) or mixed (50-94%, n¼3;
6-49%, n¼3) donor CD3+ T-cell chimerism. One patient
with sickle cell disease who received a very low total
nucleated cell dose required a stem cell boost due to poor
graft function. With a median follow-up for survivors of 12
(range, 2-35) months, the 1-year survival was 86%. Three
patients died; one died from GVHD 5 months after HCT,
one died at 4 months from an unrelated surgical compli-
cation, and one died at 8 months from recurrent CNS HLH.
None of the patients developed sinusoidal obstructive
syndrome. One patient was intubated for airway protec-
tion in the setting of herpes stomatitis. The cumulative
incidence of grades III-IV acute GVHD at 100 days and 1-
year chronic GVHD were 12% and 25%, respectively.
Patients who received ATG had a signiﬁcantly lower inci-
dence of grade III-IV acute GVHD (0% compared to 33%;P ¼ .02). Our results to date indicate that the combination
of treosulfan, ﬂudarabine, and rabbit ATG is effective at
establishing donor engraftment with a low toxicity proﬁle.
These results suggest that the reduction of regimen-
related toxicities will translate into improved survival
outcomes in patients with PIDD and other non-malignant
diseases, and support the need for future disease-speciﬁc
clinical trials.
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From August 2000 to November 2011, 127 children
under the age of 18 years with acquired severe aplastic
anemia (SAA) received hematopoietic stem cell trans-
plantation (HSCT) in one of the 10 Asia Paciﬁc institutions
of the VABMT Consortium, including 53 with matched
sibling donor (MSD) and 74 with alternative donor (AD).
Among these 74 AD, 22 were matched unrelated donor
(MUD), 32 were mismatched unrelated donor (MMUD) and
20 were mismatched related donor (MMRD). Although the
MSD group developed less grade II-IV acute GVHD
compared to the AD group (14.3% vs 32.8%, P ¼ .029), there
was no signiﬁcant difference in grade III-IV GVHD (10.2%
vs 12.5%, P ¼ .774) or chronic GVHD (19.6% vs 35.0%, P ¼
.088). After a median follow-up of 33.5 months, the inci-
dence of graft failure and 3-year overall survival were
